Clinical Trials Logo

Prostate Cancer Screening clinical trials

View clinical trials related to Prostate Cancer Screening.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04601272 Completed - Clinical trials for Breast Cancer Screening

Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions

Start date: September 29, 2020
Phase:
Study type: Observational

The purpose of this retrospective observational study is to evaluate the performance of the Shared Decision Making Process scale in a sample of patients who have received a decision aid about the decision to screen or not screen for breast cancer, colon cancer, prostate cancer, or lung cancer.

NCT ID: NCT04063566 Completed - Prostate Cancer Clinical Trials

ReIMAGINE Prostate Cancer Screening

Start date: October 21, 2019
Phase: N/A
Study type: Interventional

Single site study to assess the feasibility of prostate cancer screening using an invitation for a prostate MRI scan via GP practices. This feasibility study will assess the acceptability of an MRI as a prostate cancer screening assessment and assess the prevalence of MRI defined suspicious lesions and cancer in men across a spectrum of PSA results.

NCT ID: NCT01516801 Completed - Clinical trials for Prostate Cancer Screening

A Pragmatic Trial of the Effect of a Mailed Patient Flyer About Prostate Specific Antigen (PSA) Testing Prior to an Annual Exam

Start date: October 2009
Phase: N/A
Study type: Interventional

1. Does a one-page American College of Physicians educational flyer about the pros and cons of prostate cancer screening sent to men within two weeks of their scheduled annual health examinations in a general medicine clinic result in a different rate of prostate cancer screening than among men who were not sent the flyer? 2. Do patients find the flyer useful and understandable? Context: The use of prostate specific antigen (PSA) screening for prostate cancer is controversial because of a lack of evidence that such screening saves lives when applied within a population and because such testing can lead to invasive downstream biopsies and aggressive treatment that is associated with a high risk of permanent side effects (e.g. impotence, incontinence). Almost all professional societies (American Cancer Society, American Urologic Association, American College of Physicians, United States Preventive Services Task Force) advocate that patients receive education and complete an informed decision-making discussion with their medical providers about the pros and cons of the PSA test, as well as their personal preferences, before proceeding with this test. Unfortunately, despite these recommendations, there is seldom sufficient time during clinic visits to achieve this goal.